

# 癌症標靶治療藥物

## Bispecific antibodies

(單株抗體發展史與臨床應用)




**Clinical pharmacist: Lihua  
Fang**

**2024/09/08**

# 大綱

- 標靶治療誕生：在1975年，柯勒(Kohler)與麥爾斯坦(Milstein)將B細胞與骨髓瘤細胞(myeloma cells)成功地合成融合瘤細胞，這劃時代的創舉，便開啟了應用單株抗體的新紀元。
- 單株抗體開啟在癌症與免疫治療的新紀元
- 單株抗體的藥物命名
- 單株抗體的演化
  - 單株抗體變型
  - 雙特異性抗體 (bispecific T-cell Enganger, BiTE)-> Bispecific antibody
  - 抗體藥物複合體(antibody-drug conjugate, ADC)
  - 三功能性抗體(Trifunctional Antibody)
- 單株抗體在癌症的應用歷史與療效
  - Anti-HER2 inhibitor : Pertuzumab, Trastuzumab
  - Anti-CD20 inhibitors : Rituximab/ CD20, Obinutuzumab CD20, Ofatumumab CD20
  - VEGF inhibitors : Bevacizumab


# Complementarity determining regions (CDRs 互補決定區)



Fragment antigen-binding (Fab) is a region on an antibody that binds to antigens


FcR: B lymphocytes, NK cells, macrophages, neutrophils, and mast cells.

# Fc domain



## Function of Fc receptor

macrophages and monocytes, neutrophils, eosinophils and lymphocytes of the innate immune system (natural killer cells) or adaptive immune system (e.g., B cells). Activation of phagocytes is the most common function attributed to Fc receptors.






# The birth of monoclonal antibodies : hybridoma

1975, Nature published a three page report by César Milstein and Georges J. F. Köhler describing a method for generating large amounts of monoclonal antibodies of a predefined specificity.



César Milstein and Georges Köhler together in 1984, the year they were awarded the Nobel Prize in physiology or medicine, jointly with Niels Jerne. Photo reproduced courtesy of the Celia Milstein and the MRC Laboratory of Molecular Biology, Cambridge, UK.




**Figure 1. Production of monoclonal antibody by hybridoma technology.** The hybridoma technology outline involves the isolation of spleen cells from immunized mice, their fusion with immortal myeloma cells and the production and further propagation of monoclonal antibodies from the hybrid cells.<sup>2</sup>

# Monoclonal antibodies (單株抗體)會以人源化的程度與靶點來命名

## 人源化程度

-xi-	嵌合
-tuxi-	嵌合-人源化腫瘤 (rituximab (CD20), cetuximab)
-zu-	人源化 atezolizumab
-u-	全人類 Ramucirumab


### Different generations of Antibody therapeutics



Immunogenicity

標靶點	
-b/ba/bac	細菌感染 ibalizumab (HIV) , Raxibacumab (anthrax )
-am(i)	Serum amyloidosis protein
-ci/c-	心血管, 全身循環 Alirocumab (降血脂, 全人) Idarucizumab (reversal of dabigatran ) , bevacizumab, caplacizumab (anti-Von willebrand factor), Ramucirumab
-f(u)/fung-	真菌感染
-gros-	Skeletal muscle mass related growth factor/receptor
-ki-	白介素 canakinumab (interleukin 1), Guselkumab (intreleukin-23治療乾癬), Ixekizumab (interleukin 17A) , Risankizumab (interleukin-23), Secukinumab (interleukin 17A) : ankylosing spondylitis, psoriasis), Tildrakizumab (interleukin-23), Ustekinumab ( interleukin 12 and interleukin 23, psoriatic arthritis)
-le/les-	炎症病變 : alemtuzumab (CD52 B, T cells CELL)
-li/l-	免疫調解 : adalimumab (TMF), basilixumab, Belimumab, Brodalumab (IL-17receptor), daclizumab (interleukine 2) , Dupilumab (interleukin-4)receptor , Eculizumab (complement inhibitor), Golimumab (TNF), infliximab (TNF), Lanadelumab (kallikrein), Ocrelizumab (CD20), Ravulizumab (complement inhibitor), Sarilumab (interleukin 6 receptor), Vedolizumab (selective adhesion-molecule), nivolumab, pembrolizumab, atezolizumab, cemiplimab, Durvalumab, Ipilimumab,
-ne/n-	神經系統
-so/os/s	骨科 : Denosumab,
-tox/toxa-	毒素 Bezlotoxumab (clostridioides ) , Obiltoxaximab (anthrax) 解毒劑
-tu/t-	腫瘤 rituximab (CD20), cetuximab (EGFR), ofatumumab, teprotumumab (thyroid Ca), blinatumomab (CD/19/CD3), daratumumab (CD38), Elotuzumab (SLAM-7), Dinutuximab (GD2), Gemtuzumab, ibrutumomab ( CD20-zevalin Y-90), Inotuzumab (CD22), Sacituzumab (Trop-2)
-vi/v-	病毒 palivizumab (RSV), REGEN-COV (Casirivimab/imdevimab)
例外	Ranibizumab (AMD) 相關性黃斑部退化 (age related macular degeneration, AMD)

### Fragment Name




Fragment Name	MW	Notes
F(ab') <sub>2</sub>	≈ 110 kD	bivalent with 2 antigen binding sites joined by disulfide bonds
Fab'	≈ 55 kD	monovalent; formed by reduction of F(ab') <sub>2</sub> ; free sulfhydryl
Fab	≈ 50 kD	monovalent, consisting of VH, CH1, VL, and CL; disulfide linked
Fv	≈ 25 kD	monovalent, consisting of VH and VL chains non-covalently bound that form a single antigen binding site
Fc	≈ 50 kD	no antigen binding; mediates antibody effector functions; disulfide and non-covalently linked CH2 and CH3 regions

created in BioRender.com

### Brolucizumab

A humanized single-chain antibody fragment that inhibits all isoforms of VEGF-A



Smallest of the anti-VEGF antibodies



small molecular weight + higher molar doses + high drug concentration


### Brolucizumab

6 mg in a single intravitreal injection  
Brolucizumab





# Bispecific antibodies




- **Constructs vary in antigen-binding domains and dimerization (homodimers vs heterodimers) resulting in differences in antigen-binding sites (valency), size, geometry, and flexibility**
  - Fc portion provides stability in circulation allowing for intermittent (instead of continuous) dosing, it can also promote ADCC and complement activation
  - These variables bestow different pharmacokinetic and pharmacodynamic properties
- **T cells brought to close proximity in cells expressing MM antigen, form an immunologic synapse and promote cell-mediated cytotoxicity via release of perforin and granzymes**
- **Bispecific NK-cell engagers are currently in development**

Images are representative schematics only.

Lancman G, et al. *Hematology Am Soc Hematol Educ Program*. 2020:264-271.

# Trispecific antibodies



# Efficacy will depend

- Cancer Driven gene
- Fc function
- Properties of human IgG subclasses.

	IgG1		IgG2		IgG3		IgG4	
<b>General</b>								
Molecular mass (kD)	146		146		170		146	
Amino acids in hinge region	15		12		62 <sup>a</sup>		12	
Inter-heavy chain disulfide bonds	2		4 <sup>b</sup>		11 <sup>a</sup>		2	
Mean adult serum level (g/l)	6.98		3.8		0.51		0.56	
Relative abundance (%)	60		32		4		4	
Half-life (days)	21		21		7/~21 <sup>a</sup>		21	
Placental transfer	++++		++		++/++++ <sup>a</sup>		+++	
<b>Antibody response to:</b>								
Proteins	++		+/-		++		++ <sup>e</sup>	
Polysaccharides	+		+++		+/-		+/-	
Allergens	+		(-)		(-)		++	
<b>Complement activation</b>								
C1q binding	++		+		+++		-	
<b>Fc receptors</b>								
FcγRI	+++ <sup>c</sup>	65 <sup>d</sup>	-	-	++++	61	++	34
FcγRIIa <sub>H131</sub>	+++	5.2	++	0.45	++++	0.89	++	0.17
FcγRIIa <sub>R131</sub>	+++	3.5	+	0.10	++++	0.91	++	0.21
FcγRIIb/c	+	0.12	-	0.02	++	0.17	+	0.20
FcγRIIIa <sub>F158</sub>	++	1.2	-	0.03	++++	7.7	-	0.20
FcγRIIIa <sub>V158</sub>	+++	2.0	+	0.07	++++	9.8	++	0.25
FcγRIIIb	+++	0.2	-	-	++++	1.1	-	-
FcRn (at pH < 6.5)	+++		+++		++/++++ <sup>a</sup>		+++	

# Bispecific antibody design

- Simultaneously target two different antigens, enhancing their effectiveness against cancer.
- With or without an Fc region. IgG-like bispecifics contain an Fc region, allowing them to activate immune cells via mechanisms like ADCC and ADCP, but they may face limitations in tissue penetration and can cause off-target effects.
- Non-IgG-like bispecifics, lacking an Fc region, are smaller and offer better tissue penetration, though they require frequent dosing due to shorter half-lives.
- Various designs, including trivalent and multispecific formats, improve tumor specificity by targeting multiple antigens or activating immune pathways.
- Modulating affinity and valency : Adjusting affinities for CD3 or tumor-associated antigens (TAAs) further optimizes therapeutic potential and reduces off-target toxicity.
- To enhance specificity, tumor penetration, and the ability to modulate the tumor microenvironment, marking an exciting future for bispecific antibody therapies.
- >200 bispecific antibodies, with increasingly diverse designs and mechanisms of action, are currently in preclinical or clinical development

# Bispecific and multispecific antibodies in oncology

## Bispecific T cell engager

- CD20 × CD3 Odronextamab (RR FL, RR DLBCL )
- BCMA × CD3 Linvoseltamab (RR MM )

## Dual signalling pathway inhibition

- HER2 × HER2 (advanced and/or metastatic HER2-amplified biliary tract cancer BTC )

## Bispecific NK cell engager






- CD30 × CD16 (NHL)


## Dual checkpoint inhibition

- PD-1 × CTLA4 ( ccRCC, clear-cell renal cancer, NSCLC, TNBC)
- PD-1 × VEGF (advanced-stage EGFR/ALK wild type NSCLC )





# Comparative characteristics of CD20XCD3 BsAb currently in development

Product name	Schematic depiction	Format	Technology	CD20:CD3 ratio	CD3 clone	CD20 clone	Fc silencing mutations*
Mosunetuzumab <sup>18</sup>		IgG1	Knobs-into-holes (different Fabs)	1:1	UCHT1v9 (CD3δε)	2H7 (type 1 epitope, identical to rituximab)	N297G (no FcγR binding)
Glofitamab <sup>15</sup>		IgG1	Head-to-tail fusion	2:1	SP34-der. (CD3ε)	By-L1 (type 2 epitope, identical to obinutuzumab)	IgG1-P329G-LALA (no FcγR binding)
Epcoritamab <sup>16</sup>		IgG1	Controlled Fab-arm exchange	1:1	huCACAO (SP34-der.) (CD3ε)	7D8 (type 1 epitope, shared by ofatumomab)	L234F,L235E,D265A (no FcγR,C1q binding)
Odronexamab <sup>17</sup>		IgG4	Heavy chains with different affinity	1:1	REG1250 (CD3δε)	3B9-10 (type 1 epitope, shared by ofatumomab)	Modified IgG4 (no FcγRIII binding)
Plamotamab <sup>90</sup>		IgG1	Fab-Fc x scFv-Fc	1:1	α-CD3_H1.30 (SP34-der.) (CD3ε)	C2B8_H1_L1 (type 1 epitope, shared by rituximab)	G236R, L328R (no FcγR binding)



# Comparative characteristics of CD20XCD3 BsAb currently in development

IgM 2323 <sup>19</sup>		IgM	IgM + modified J chain	10:1	Not reported	Not reported	No
------------------------	---	-----	------------------------	------	--------------	--------------	----



Agent	Target	Indication and activity	Common grade ≥3 adverse events	Year of approval
<b>Blinatumomab</b>	CD3 × CD19	RR B-ALL: CR/CRh in 43–44%, mRFS 5.9 months, mOS 6.1–6.9 months	Neutropenia (37.8–41%), infection (34.1%), elevated circulating liver enzymes (6–12.7%), neurological events (9.4–11%), CRS (4.9%)	2014 <sup>a</sup> , 2017 (FDA); Subsequently, MRD <sup>+</sup> B-ALL
<b>Mosunetuzumab</b>	CD3 × CD20	RR FL: CRR 60%, ORR 80%, mPFS 17.9 months, mOS NR	Neutropenia or reduced neutrophil count (26%), hypophosphataemia (17%), anaemia (8%), increased serum ALT (5%), CRS (2%)	2022 <sup>a</sup> (EMA), 2022 <sup>a</sup> (FDA)
<b>Tebentafusp</b>	CD3 × gp100–HLA-A*02:01	HLA-A*02:01-positive uveal melanoma: ORR 11%, mPFS 3.4 , mOS 21.6 months	Rash (19%), elevated circulating liver enzymes (10%), pyrexia (5%), pruritus (5%), CRS (1%)	2022 (FDA), 2022 (EMA)
<b>Teclistamab</b>	CD3 × BCMA	RR MM: CRR 39.4%, ORR 63%, mPFS 11.3 months, mOS 18.3 months	Neutropenia (64.2%), anaemia (37.0%), lymphopenia (32.7%), thrombocytopenia (21.2%), CRS (0.6%)	2022 <sup>a</sup> (FDA), 2022 <sup>a</sup> (EMA)
<b>Glofitamab</b>	CD3 × CD20	RR DLBCL: CRR 39%, ORR 52%, mPFS 4.9 months, mOS 12 months	Neutropenia (27%), thrombocytopenia (8%), anaemia (6%), CRS (4%)	2023 <sup>a</sup> (FDA), 2023 <sup>a</sup> (EMA), 2023 <sup>a</sup> (NMPA)
<b>Epcoritamab</b>	CD3 × CD20	RR DLBCL: CRR 38.9%, mPFS 4.4 months, mOS NR	Neutropenia (14.6%), anaemia (10.2%), thrombocytopenia (5.7%), CRS (2.5%)	2023 <sup>a</sup> (FDA) 2023 <sup>a</sup> (EMA)
<b>Elranatamab</b>	CD3 × BCMA	RR MM: ORR 61%, estimated 15-month PFS 50.9%, estimated 15-month OS 56.7%	Neutropenia (48.8%), anaemia (37.4%), lymphopenia (25.2%), thrombocytopenia (23.6%)	2023 <sup>a</sup> (FDA), 2024 <sup>a</sup> (EMA)
<b>Talquetamab</b>	CD3 x PRC5D	RR MM: ORR 72%, mDOR 9.5 months, mPFS NR	Lymphopenia (47%), anaemia (33%), neutropenia (26%), leukopenia (16%)	2023 <sup>a</sup> (FDA)
<b>Tarlatamab</b>	CD3 x DLL3	RR SCLC: ORR 40%, mDOR 9.7 months, mPFS 4.9 months	CRS (26%), neutropenia (8%)	2024 <sup>a</sup> (FDA)
<b>Amivantamab</b>	EGFR × MET	Advanced-stage NSCLC ( EGFR exon 20 insertion mutations (in combination with chemotherapy): ORR 73%, mPFS 11.4 months, mOS NR	Neutropenia (33%), rash (11%), leukopenia (11%), anaemia (11%), thrombocytopenia (10%)	2021 <sup>a</sup> (FDA)
<b>Cadonilimab</b>	PD-1 × CTLA4	Advanced-stage cervical cancer: ORR 32.3%, mPFS 3.7 months, mOS NR	Anaemia (5%), reduced appetite (4%), dyspnoea (2%)	2022 (NMPA)

Relapsed or refractory (R/R) B-cell lymphoma

# Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

- Platinum-based combinations followed by high-dose therapy and autologous stem cell support (ASCS) as 2<sup>nd</sup> line therapy, with an 15%–20% cure rate in the rituximab era
- Advent of targeted agents
  - polatuzumab vedotin (CD79b), tafasitamab(CD19), loncastuximab(CD19) have resulted in incremental benefits for patients with R/R DLBCL
- T-cell-based immunotherapies
  - CAR- T cells (axicabtagene ciloleucel and lisocabtagene maraleucel ): durable remissions 30%–40% ( limited access outside large tertiary care centers, complex insurance approval processes, high costs, limited manufacturing capability, and potentially long product turnaround, among others.)
- Bispecific antibodies (BsAbs)
  - off-the-shelf T-cell redirecting drugs with promising activity in B-cell non-Hodgkin lymphoma and the potential to play a major role in the treatment of R/R DLBCL.



Antibody	Obinutuzumab	Rituximab	Ofatumumab
Trade name (EU)	Gazyvaro	MabThera	Arzerra
Manufacturer	Roche	Roche	GlaxoSmithKline
Antibody type	II	I	I
IgG subclass	IgG1	IgG1	IgG1
Structure	Humanized	Chimeric	Fully human
Binding to CD20 epitope	Large loop	Large loop	Large and small loop
Binding to lipid rafts	-	++	++++
ADCC	++++	++	++
CDC	+	++	++++
Direct cell death induction	++++	+	+

**Abbreviations:** ADCC, antibody-dependent cellular cytotoxicity; CDC, complement-dependent cytotoxicity; I Ig, immunoglobulin.

Comparison of commercially available anti-CD20 antibodies




Fig.1 Mechanism of action of obinutuzumab


# Conclusion


- Obinutuzumab : significant improvement in PFS
  - No improvements in OS, ORR and CRR, and an increment in the incidences of AEs.
- Ofatumumab comparable results in PFS, OS and CRR
  - a lower ORR and higher incidences of AEs.
- 131-tositumomab
  - similar results with rituximab regarding PFS, OS, ORR and CRR but was associated with higher incidences of AEs.
- 90Y-ibritumomab achieved a higher ORR, similar PFS, OS and CRR
  - higher incidences of AEs.

# Landscape of effector cellular therapy for DLBCL therapy.

Bispecific T cell engagers (left) include BiTEs like blinatumomab, fused full-length antibodies like the DLBCL-approved products epcoritamab and glofitamab, and multivalent constructs like imovtamab. Approved CAR-19 therapies (top right) are manufactured ex vivo from each patient's T cells, requiring 20–40 days. Viral or nanoparticle delivery of CAR genes (bottom right) in vivo is one of many investigational ways to potentially accelerate targeted cell therapy delivery.

Blood Cancer J. 14, 27 (2024).







Mechanism of action of antiCD20 and antiCD3 bispecific antibodies. Mosunetuzumab, IgG1 ab with a rituximab-like antiCD20 domain; epcoritamab, IgG1 ab with an ofatumumab-like antiCD20 domain; glofitamab, IgG1 ab with a ratio 2:1 CD20:CD3 and an obinutuzumab-like antiCD20 domain; odronextamab, IgG4 ab with an ofatumumab-like antiCD20 domain. Illustration created with biorender-individual version.



# Currently Approved Indications

- **Glofitamab:** Adult relapsed/refractory **DLBCL**, not otherwise specified or large B-cell lymphoma arising from FL who have received 2 or more prior lines of systemic therapies (2023, June approved)
- **Epcoritamab:**
  - Adults with relapsed/refractory **DLBCL** and high-grade DLBCL, not otherwise specified, including DLBCL arising from indolent lymphoma, after 2 or more lines of systemic therapy (2023, May approved)
  - Adult patients with relapsed or refractory **FL** after 2 or more lines of systemic therapy (2024, June approved)






Blood (2023) 141 (5): 467–480.

- Other common adverse events (AE): Neutropenia, diarrhea, fatigue, anemia;
- ICANS-like syndrome, TLS, HLH: rare (<5%)
- \* data for aggressive NHL and indolent NHL reported in aggregate


# CD20/CD3 Bispecific Antibodies in B-Cell Lymphomas

Humanized mouse IgG1-based mAb




**Epcoritamab  
(SC)**

3L+ R/R DLBCL



**Glofitamab  
(IV)**

3L+ R/R DLBCL



**Odronextamab  
(IV)**

Approval Status: Priority Review for 3L+ R/R FL and DLBCL



Antibody Name	Trial Name ( Pt Number)	Indication	ORR	PFS	Overall Survival (OS)	Adverse Events	Source of Journal
<b>Mosunetuzumab (Rituximab)</b>	GO29781 (90 pts)	R/R Follicular Lymphoma after at least two prior therapies	ORR : 77.8% CR : 60 % Median DOR : NR; 79.5% of complete responders at least 24 months	24-month PFS: 51.4%	Not yet mature in published data	CRS, Neutropenia, Fatigue	Blood. 2022;140(suppl 1):1467-1470.
<b>Glofitamab (obinutuzumab)</b>	NP30179 (155 pts)	R/R Diffuse Large B-Cell Lymphoma (DLBCL) after at least two prior therapies	ORR :52% CR : 39% CR (CAR-T) : 35%. The median time to a complete response : 42 days	The 12-month PFS : 37% ) At 12 months CR : 78%		CRS, Neutropenia, Infections	N Engl J Med 2022;387:2220-2231
<b>Epcoritamab (Ofatumumab)</b>	EPCORE NHL-1 (157 pts)	R/R DLBCL after prior therapies	ORR 63.1% and CR39.5%,	The mDoCR : 20.8 mo Median time to CR : 2.7 mo;	mOS : 18.5 mo	CRS, Pyrexia, Neutropenia	JCO Volume 41, Number 16_suppl
<b>Odronextamab (Ofatumumab)</b>	ELM-2 (375 pts) (across five cohorts)	R/R DLBCL and FL	DLBCL (CAR T-cell naive): ORR: 50.8; CR: 31.6%; FL: ORR: 80%; CR: 73.4%	DLBCL: mDCR : 36.3 months FL: Median DCR : 25.1 months mPFS: 20.7 months	FL: m OS: Not reached	CRS, pyrexia, anemia, neutropenia;	Annals of Oncology, 2024 Nov;35(11):1039-1047 Blood (2024) 144 (Supplement 1): 3118.

# Single-agent clinical efficacy (Mosunetuzumab )



- Indication : with R/R FL after  $\geq 2$  prior lines of therapy
- Among 197 subjects, 43 were treated at a target dose of 13.5 mg, and 154 at 30 mg.
  - 1/3 follicular lymphoma (FL), 2/3 B-NHL (aNHL).
  - The median number of prior therapies : 3.
  - CAR T-cell therapy : 10%
  - aNHL : ORR, CR, mDOR (35%, 19%, and 7.6 months), mPFS : 1.4 months
  - indolent NHL : ORR, CR, mDOR, mPFS ( 66%, 48%, 16.8 months, and 11.8 months)
- IV or SC formulations
- 90 pts (the target dose of 30 mg)
  - R/R FL
  - ORR : 80% , CR : 60%.
  - The median DOR and PFS ( 22.8 months and 17.9 months ), 18-month OS rate : 90%

# Glofitamab




- Indication: R/R diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of therapy.
- 171 pts with CD20 (+) B-NHL previously a median of 3 prior lines of therapy
  - a single 1000 mg dose of pretreatment obinutuzumab followed by fixed or step-up dosing IV glofitamab every 2 or 3 weeks.
    - Dose-dependent clinical activity starting at 0.6 mg, and at doses  $\geq 10$  mg the ORR among patients with aNHL was 61%, including 49% CR.
- 155 pts with aNHL treated with glofitamab ( target dose of 30 mg) NP30179
  - ORR and CR ( 52% and 39%), CR rate : CAR T-cell therapy (35%) and not CAR-T (42%).
  - Median follow-up of 12.6 months, the median DOR was 18.4 months, the PFS was 4.9 months, and the OS was 11.5 months.
- R/R FL
  - Deep tumor volume reductions were observed regardless of obinutuzumab administration.
- R/R mantle cell lymphoma
  - ORR (81%) , CR (67%) regardless of prior Bruton tyrosine kinase inhibitor therapy.





# Epcoritamab

Epcoritamab <sup>16</sup>		IgG1	Controlled Fab-arm exchange	1:1
---------------------------	--	------	-----------------------------	-----

- **Indication**

- R/R follicular lymphoma after 2 or more lines of therapy.
- R/R third-line diffuse large B-cell lymphoma (DLBCL). (SC)
- 73 pts with R/R B-NHL at doses ranging from 0.0128 to 60 mg.
  - SC initially weekly, then every 2 weeks, then every 28 days.
  - 22 pts with aNHL treated at doses between 12 mg (the minimum clinically active dose) and 60 mg, the ORR (68%) and CR (45%). At a median follow-up of 9.2 months, 75% remained relapse-free for at least 6 months.
- 157 pts R/R aNHL
  - ORR and CR (63% and 39%)
  - CAR-T-naïve (ORR, 69%; CR, 42%) vs CAR-T-exposed (ORR, 54%; CR, 34%) individuals.
  - At the 12-month mark, 80% of CRs were maintained, and 67% of patients were alive.
- 127 pts Phase 1/2 EPCORE NHL-1 study (R/R) follicular lymphoma (FL)
  - ORR : 82% with CR : 60%. mPFS : 15.4 months, mDOR, duration of CR, and OS were not reached, minimal residual disease (MRD) negativity was associated with improved PFS.

# Odronextamab (Ofatumumab)

- Indication
  - R/R follicular lymphoma and R/R diffuse large B-cell lymphoma (DLBCL), both after 2 or more lines of systemic therapy.
- 127 pts ELM-2 trial R/R DLBCL
  - ORR : 52% (naive to CAR T) , CR : 31.5%, and mDOR : 10.2 months
  - ORR : 33.3% and CR : 26.7%. (CART)
  - At 24 months, the CR rate was maintained in 47%
- 121 pts ELM-2 trial R/R follicular lymphoma (median follow-up of 22 months )
  - ORR : 82% and CR : 75%. Duration of CR: 20.5 months, mPFS : 20 months , OS not yet reached



# Deciding Between Available Bispecific Antibodies and Other 3L+ Treatments for R/R DLBCL

- **How do bispecific antibodies compare to other therapies?**
  - “Off the shelf” option (availability): means we can give right away whereas therapies like CAR T-cells require adequate cell collection, manufacturing time, etc
  - **Safety profiles:**
    - Lower toxicity risks/safer: including for patients not good candidate for CAR T-cell therapy
    - Shorter hospitalization times
    - Different targets (CD20 vs CD19) which means that CAR T-cell does not preclude bispecific antibody and vice versa
- **What are the advantages for bispecific antibodies over chemotherapy?**
  - Improved efficacy, potentially better safety and/or improved QoL



# Deciding Between Available Bispecific Antibodies: Which One Is Best for Each Patient?

## Choosing Between Glofitamab vs Epcoritamab for DLBCL

- Safety and efficacy were similar in pivotal trials
- Inpatient observation recommended for both
- **Glofitamab has a fixed duration (21-day cycle x 12) and less frequent administration**
- **Glofitamab does not require steroids for CRS mitigation**
- Epcoritamab does not require obinutuzumab use for tumor volume reduction

# Comparison of structure, administration, CRS, and neurotoxicity associated with CD3×CD20 BsAbs in NHL

Drug	Mosunetuzumab	Epcoritamab	Glofitamab	Odronextamab
Structure	Fully humanized IgG1 CD3×CD20 BsAb with 1:1 CD3:CD20 ratio of Fab arms	IgG-like anti-CD3×CD20 BsAb. Proprietary format, with point mutations in the Fab portion of the Fc of the antibody and heterodimerization.	Humanized mouse-derived BsAb with 1:2 CD3:CD20 ratio of Fab arms	Fully humanized IgG4 anti-CD3×CD20 BsAb developed using an Fc domain with a mutation in the protein A of the Fc portion
Route of administration	IV	SC	IV	IV
Dosing schedule	C1: days 1, 8, 15; C2+: day 1, every 21 d, for up to 8 cycles in CR or up to 17 cycles for PR or SD	C1-3: days 1, 8, 15, and 22; C4-9: days 1 and 15; C10+: day 1, every 28 d until progression	C1: obin, day 1; glofit, days 8 and 15; C2-12: day 1, every 21 d	C1: days 1, 2, 8, 9, 15, 16 of a 21-d cycle; C2-4: days 1, 8, 15 of a 21-d cycle; C5+: day 1, every 14 d; If CR for at least 9 mo: day 1, every 28 d
CRS mitigation				
Step-up dosing	C1D1: 1 mg C1D8: 2 mg C1D15: 60 mg C2D1: 60 mg C3+D1: 30 mg  Blood (2024)	C1D1: 0.16 mg C1D8: 0.8 mg C1D15: 48 mg C1D22: 48 mg C2D1+: 48mg  143 (16): 1565–1575.	C1D1: obin 1000 mg C1D8: 2.5 mg C1D15: 10 mg C2D1+: 30 mg	C1D1: 0.2 mg, C1D2: 0.5 mg C1D8: 2 mg, C1D9: 2 mg C1D15: 10 mg, C1D16: 10 mg C2-C4: 80 mg (FL) or 160 mg (DLBCL) C5+: 160 mg (FL) or 320 mg (DLBCL)





Drug	Mosunetuzumab					Epcoritamab					Glofitamab					Odronextamab				
Premedications	<ul style="list-style-type: none"> <li>A/P 500-1000 mg, 30 min prior, for C1 and C2</li> <li>Diphenhydramine 50-100 mg, 30 min prior, for C1 and C2</li> <li>Dexamethasone 20 mg or MP 80 mg, 1 h prior, for C1 and C2. Continue all premedications if CRS with prior dose.</li> </ul>					<ul style="list-style-type: none"> <li>A/P 650-1000 mg, 30-120 min before C1 treatments</li> <li>Diphenhydramine 50 mg, 30-120 min before C1 treatments</li> <li>Dexamethasone 15 mg, 30-120 min before C1 treatments and for 3 consecutive days after. Continue dexamethasone thereafter if G2 or G3 CRS with prior dose.</li> </ul>					<ul style="list-style-type: none"> <li>A/P 500-1000 mg, 30 min before all treatments</li> <li>Diphenhydramine 50 mg, 30 min before all infusions</li> <li>Dexamethasone 20 mg, 1 h before treatment on C1D8, C1D15, C2D1, and C3D1. Continue if CRS with prior dose.</li> </ul>					<ul style="list-style-type: none"> <li>A/P 650 mg, 30-60 min before all treatment</li> <li>Diphenhydramine 25 mg, 30-60 min prior before all infusion</li> <li>Dexamethasone 10 mg orally, 12-24 h before split dose, 20 mg IV on day of dosing, 10 mg orally on the day after step-up dosing. Following first full dose, dexamethasone 10 mg before dosing; continue if CRS with prior dose.</li> </ul>				
住院	Optional					C1D15: 24-h admission					C1D8: 24-h admission					Performed during step-up dosing				
CRS grading	G1	G2	G3	G4	G5	G1	G2	G3	G4	G5	G1	G2	G3	G4	G5	G1	G2	G3	G4	G5
	26%	17%	1%	1%	0%	34%	15%	3%	0%	0%	47%	12%	3%	1%	0%	35%-39%	13%	0%	0%	0%
	Time course for CRS onset			Median time (h) to CRS onset		Time course for CRS onset			Median time (h) to CRS onset		Time course for CRS onset			Median time (h) to CRS onset		Time course for CRS onset			Median time (h) to CRS onset	
	C1D1: 23.3%			C1D1: 5		C1D1: 5.8%			All doses: 24		C1D8: 42.8%			C1D8: 13.5 (range: 6-52)		C1D1/2: 22%-24%			All doses: 18-20	
	C1D8: 5.6%			C1D8: 20		C1D8: 11.8%			C1D15: 20		C1D15: 25.2%					C1D8/9: 27%-32%				
	C1D15: 36.4%			C1D15: 27		C1D15: 42.8%					C2: 26%					C1D15/16: 21%-35%				
	C2D1: 10.3%			C2D1: 38		C1D22: 4.9%					C3+: 0.9%					C2D1: 14%-17%				
	C3+D1: 2.4%					C3+ 3%										C2D8+: 9%-14%				
Median duration of CRS	3 d (1-29 d)					2 d (range: 1-27 d)					30.5 h (range, 0.5-317 h)					8-10 h (range, 0.1-190 h)				
Neurotoxicity	G 1-2		G3	G4	G5	G1	G2	G3	G4	G5	G 1-2		G 3-4		G5	G 1-2		G 3-4		G5
	3%		0%	0%	0%	4.5%	1.3%	0%	0%	0.6%	5%		3%		0%	4% (DLBCL)		0%		0%

# Glofitamab: Dosing and Administration

- Intravenously administered in 21-day cycles for 12 cycles
- **CD20 antibody obinutuzumab given prior to first dose** to reduce risk of toxicity by decreasing tumor burden
- **Hospitalization recommended** for 24 hr after step-up dose 1 and if CRS with prior dose

Treatment Cycle	Day	Dose	Infusion Duration	Premedication
Cycle 1	1	Obinutuzumab 1000 mg at 50-400 mg/hr (deplete circulating B-cells)		<ul style="list-style-type: none"> <li>▪ N/A</li> </ul>
<ul style="list-style-type: none"> <li>▪ Step-up dose 1</li> <li>▪ Step-up dose 2</li> </ul>	8 15	2.5 mg IV 10 mg IV	4 hr 4 hr <sup>†</sup>	<ul style="list-style-type: none"> <li>▪ IV dexamethasone* 20 mg completed ≥1 hr before infusion</li> <li>▪ PO/IV diphenhydramine 50 mg (or an equivalent) and PO acetaminophen 500-1000 mg ≥30 min before infusion</li> </ul>
Cycle 2	1	30 mg IV	4 hr <sup>†</sup>	<ul style="list-style-type: none"> <li>▪ Same as cycle 1 Day 8 and 15 guidance</li> </ul>
Cycle 3	1	30 mg IV	2 hr <sup>‡</sup>	<ul style="list-style-type: none"> <li>▪ Same as cycle 1 Day 8 and 15 guidance</li> </ul>
Cycle 4-12	1	30 mg IV	2 hr <sup>‡</sup>	<ul style="list-style-type: none"> <li>▪ PO/IV diphenhydramine 50 mg (or an equivalent) and PO acetaminophen 500-1000 mg ≥30 min before infusion</li> <li>▪ <i>If CRS occurred with previous dose, add IV dexamethasone* 20 mg completed ≥1 hr before infusion</i></li> </ul>

\*If dexamethasone unavailable, administer IV prednisone 100 mg, prednisolone 100 mg, or methylprednisolone 80 mg. †Infusion time may be extended to up to 8 hr, if CRS occurred with previous dose. ‡Infusion time should be kept at 4 hr, if CRS occurred with previous dose.

# Epcoritamab Dosing and Administration


- Subcutaneous injection
- Administered in 28-day cycles for  $\geq 10$  cycles total
- **Hospitalization recommended** for 24 hr after Cycle 1 Day 15 dose

Treatment Cycle	Day	Dose	Premedication
Cycle 1 ▪ Step-up dose 1 ▪ Step-up dose 2 ▪ Step-up dose 3 (first full dose) ▪ Target dose	1 8 15 22	0.16 mg SC 0.8 mg SC 48 mg SC 48 mg SC	<ul style="list-style-type: none"> <li>▪ PO/IV prednisolone 100 mg or dexamethasone 15 mg (or an equivalent) for 30-120 min before weekly administration <i>and</i> for 3 consecutive days after each dose</li> <li>▪ PO/IV diphenhydramine 50 mg and PO acetaminophen 650-1000 mg for 30-120 min before weekly administration</li> </ul>
Cycle 2-3	1, 8, 15, 22	48 mg SC	<ul style="list-style-type: none"> <li>▪ <i>For grade 2/3 CRS with prior dose:</i> PO/IV prednisolone 100 mg or dexamethasone 15 mg (or an equivalent) for 30-120 min before weekly administration <i>and</i> for 3 consecutive days after dose</li> </ul>
Cycle 4-9	1, 15	48 mg SC	<ul style="list-style-type: none"> <li>▪ Same as cycle 2-3</li> </ul>
Cycle 10 and beyond	1	48 mg SC	<ul style="list-style-type: none"> <li>▪ Same as cycle 2-3</li> </ul>

# Glofitamab and Epcoritamab: Clinical Trial Data Efficacy and Safety Summary

Bispecific	ORR	CR	Median DoR	Median PFS	Median Time to CR	CRS Incidence	ICANS Incidence	Cytopenias Grade 3/4	Serious Infections
<b>Glofitamab</b>	51.6%	39.4%	26.9 mo	12.1 mo	43.0 days	G1: 48% G2: 12% G3: 3% G4: 1%	G1/2: 5.0% G3/4: 3.0%	Neut: 26% Anemia: 8% Thromb: 8% Lymph: 83%	G3/4: 16.0% Fatal: 4.8%
<b>Epcoritamab</b>	63.0%	39.0%	15.5 mo	4.4 mo	2.7 mo	G1: 32% G2: 16% G3: 3% G4: 0%	G1: 4.5% G2: 1.3% G3: 0% G4: 0%	Neut: 32% Anemia: 12% Thromb: 12%	G3/4: 15.0% Fatal: 1.3%

# Comparison of CAR-T cell therapy and Bispecific antibodies as 3-line or later treatment for diffuse large B-cell lymphoma: A meta- analysis






# Comparison of CAR T-cell and bispecific antibody as third-line or later-line treatments for multiple myeloma: a meta-analysis

Journal for ImmunoTherapy of Cancer  
2024;12:e010064.

- Results CAR-T-cell therapy achieved significantly higher pooled CR rate (0.54 (95% CI 0.42–0.69) vs bispecific antibodies 0.35 (0.30–0.41),  $p < 0.01$ ) and pooled ORR (0.83 (0.76–0.90) vs 0.65 (0.59–0.71),  $p < 0.01$ ).

**Figure 1.** Response rates reported with BCMA CAR-T and bsAbs/BiTEs<sup>1</sup>



1. Session V. 3rd European CAR-T cell Meeting; Feb 5, 2021; Virtual.

# **AE Identification and Management and/or Addressing Barriers to Treatment**

# Selected risk-adapted strategies to mitigate CRS

- **Analyses of factors that define the risk of CRS**

- Antibody format
- Modulating CD3 binding domains and their affinity
- Clinical dosing strategies (such as use of priming doses or step-up dosing)
- Quantitative cytokine modelling (using induced cytokine levels to guide subsequent dosing)
- Route of administration (intravenous versus subcutaneous)
- Composition of the redirected effector cell population (pan-T cell populations versus CD8<sup>+</sup> T cells or tissue-resident T cells, NK cells and/or macrophages)
- Indication (haematological malignancies or solid tumours expressing specific targets)
- Tumour burden

- **Strategies to prevent severe CRS**

- Pre-infusion risk assessment
- Pre-infusion risk mitigation (such as debulking to reduce the size of the antigen compartment)

- Pre-emptive strategies: early tocilizumab or steroids in patients with low-grade CRS
- Optimize supportive care (including the use of intravenous fluids)

- **Pharmacological approaches to treat CRS**

- Treatment interruption or discontinuation
- Glucocorticoids
- Cytokine-targeted strategies
  - IL-6R/IL-6 inhibitors (tocilizumab, siltuximab)
  - IL-1 inhibitors (anakinra)
  - Inhibitors of TNF (for example, etanercept) or IFN $\gamma$  (emapalumab)

- **Innovative approaches to prevent CRS**

- Pretreatment with antibodies competing for the same targets
- Restricting T cell activation to the tumour site (for example, using masking strategies for conditional activation of T cell engagers)



# Summary of Key AEs With Bispecific Antibodies

- **CRS**
  - ASTCT grading
  - Incidence and timing of onset vary by disease subtype, product, administration route, and dosing schedule
  - Incidence across products: 40%-65% with majority occurring with the first step-up doses
    - Grade 1/2: 43%-70%
    - Grade 3/4: 2%-4%
  - CRS Onset (most grade 1-3/grade 4-5): Cycle 1 Day 15 / between Cycle 1 Day 15 and Cycle 2 Day 1
- **Neurotoxicity: ICANS**
  - ASTCT grading
  - Incidence across products: 1%-8%
- Cytopenias/infections
- Tumor flare (with FL and DLBCL FDA-approved bispecific antibodies)
- Hypersensitivity reactions
- ICANS onset: N/A

# Ongoing Healthcare Professionals Challenges Regarding Novel Bispecific Therapies

Educational issues for all the team (particularly if no experience with CAR T-cell)

Guidelines for managing toxicities

Managing patients completely in the outpatient setting—safety

Infrastructure and staffing roles/requirements

Patient hand-off to community oncologist after step-up dosing

Financial concerns for facility

Availability of patient resources



# ASTCT Consensus Grading of CRS

CRS Parameter*	Grade 1	Grade 2	Grade 3	Grade 4
<b>Fever</b> <sup>*†</sup>	Temperature ≥38°C	Temperature ≥38°C	Temperature ≥38°C	Temperature ≥38°C
	<b>With either:</b>			
<b>Hypotension</b> <sup>*</sup>	None	Not requiring vasopressors	Requiring one vasopressor with or without vasopressin	Requiring multiple vasopressors (excluding vasopressin)
	<b>And/ or</b> <sup>‡</sup>			
<b>Hypoxia</b> <sup>*</sup>	None	Requiring low-flow nasal cannula (low-flow nasal cannula is ≤6 L/min and high-flow nasal cannula is >6 L/min)	Requiring high-flow nasal cannula, facemask, non-rebreather mask, or Venturi mask	Requiring positive pressure (eg, CPAP, BiPAP, intubation and mechanical ventilation)

\*Not attributable to any other cause. Organ toxicities associated with CRS may be graded according to CTCAE v5.0 but they do not influence CRS grading.

†In patients who have CRS then receive tocilizumab or steroids, fever is no longer required to grade subsequent CRS severity.

‡CRS grade is determined by the more severe event.

# 激素釋放症候群 Cytokine Release Syndrome (CRS) 評估及建議治療措施

(通常發生時間: 開始治療後 2-3 天 (但可能在幾小時內, 也可能延後到 10-15 天)。通常持續時間: 7-8 天, 根據藥物會有差異)

CRS的等級	Anti-IL-6 therapy	類固醇	建議措施
第1級 體溫 $\geq 38^{\circ}\text{C}$ , 無影響血壓或血氧	對於CRS持續時間超過3天, 且患者有顯著症狀、合併症和/或年齡超過65歲, 考慮給予單劑Tocilizumab 8 mg/kg(不超過 800mg) 靜脈輸注1小時	可考慮給予單劑dexamethasone 10 mg 並評估是否需要下一劑量	<ul style="list-style-type: none"> <li>● Fever workup並使用考慮使用廣效經驗性抗生素</li> <li>● 如果嗜中性白血球低下, 考慮使用G-CSF。</li> <li>● 給予IV fluid</li> <li>● 評估是否有Organ dysfunction</li> <li>● 觀察決定是否暫停給藥</li> <li>● 給予退燒藥做症狀治療</li> </ul>
第2級 體溫 $\geq 38^{\circ}\text{C}$ , 並有下列任一種情形: 1. 低血壓, 對輸液有反應, 且不須使用升壓劑 2. 低血氧, 須使用低流量氧氣(鼻導管或面罩)	給予Tocilizumab 8 mg/kg(不超過800mg) 靜脈輸注1小時 *若無改善, 則視需要每8時重複投予tocilizumab。24小時內最多投予3劑; 最多共可投予4劑。	如果在開始投予1-2劑tocilizumab後24小時內血壓未獲改善, 則給予methylprednisolone 1mg/kg Q12H 或 dexamethasone 10 mg Q24H to Q6H *持續使用類固醇治療, 直到副作用降至第1級或更低, 然後在3天內逐步減量。	<ul style="list-style-type: none"> <li>● 暫停給藥</li> <li>● 給予IV fluid resuscitation, 對於兩次IV fluid resuscitation和開始tocilizumab後仍持續性頑固性低血壓者, 開始使用升壓藥, 並考慮轉至ICU</li> <li>● 若在開始tocilizumab治療後24小時內沒有改善, 進入第三級治療。</li> <li>● 治療Organ dysfunction</li> </ul>
第3級 體溫 $\geq 38^{\circ}\text{C}$ , 並有下列任一種情形: 1. 低血壓, 只須使用一種升壓劑 2. 低血氧, 須使用高流量鼻導管、非再吸入型面罩	同第2級治療, 並給予methylprednisolone 1mg/kg Q12H 或dexamethasone 10 mg Q12H to Q6H		<ul style="list-style-type: none"> <li>● 轉至ICU以進行連續性血液動力學監測</li> <li>● 必要時進行插管及呼吸器治療。</li> <li>● 排除其他造成休克的原因</li> <li>● 治療Organ dysfunction</li> <li>● 通常需永久停用藥物</li> </ul>

# 激素釋放症候群 Cytokine Release Syndrome (CRS) 評估及建議治療措施

<p>第3級 體溫<math>\geq 38^{\circ}\text{C}</math>，並有下列 任一種情形： 1. 低血壓，只須使用 一種升壓劑 2. 低血氧，須使用高 流量鼻導管、非再吸 入型面罩</p>	<p>同第2級治療，並給予methylprednisolone 1mg/kg Q12H 或dexamethasone 10 mg Q12H to Q6H</p>	<ul style="list-style-type: none"><li>● 轉至ICU以進行連續性血液動力學 監測</li><li>● 必要時進行插管及呼吸器治療。</li><li>● 排除其他造成休克的原因</li><li>● 治療Organ dysfunction</li><li>● 通常需永久停用藥物</li></ul>
<p>第4級 體溫<math>\geq 38^{\circ}\text{C}</math>，並有下列 任一種情形： 1. 低血壓，須使用兩 種以上升壓劑 2. 低血氧，須使用高 正壓呼吸器或插管</p>	<p>同第2級治療，並給予 dexamethasone 10 mg Q6H 或methylprednisolone 1-2g / daily * 3 days 考慮後線免疫抑制劑如:Anakinra, siltuximab, ruxolitinib, cyclophosphamide, IVIG, ATG, intrathecal chemotherapy, or extracorporeal cytokine adsorption with continuous renal replacement therapy (CRRT)</p>	

# ICANS : 免疫作用細胞相關神經毒性症候群 Immune Effector Cell-Associated Neurotoxicity Syndrome


(ICANS) 評估及建議治療措施 (通常發生時間: 開始治療後 4-10 天。通常持續時間: 14-17 天)

Neurotoxicity Domain	Grade 1	Grade 2	Grade 3	Grade 4
ICE score	7-9	3-6	0-2	0 (patient is unarousable)
Depressed consciousness	Awakens spontaneously	Awakens to voice	Awakens to tactile stimuli only	Unarousable or needs vigorous/repetitive tactile stimuli, stupor, or coma
Seizure	N/A	N/A	Clinical seizure that is focal or generalized, resolves rapidly; nonconvulsive seizures via EEG, resolves with intervention	Prolonged seizure (>5 min) that is life-threatening or clinical or electrical seizures that are repetitive and do not return to baseline in between
Motor findings	N/A	N/A	N/A	Deep focal motor weakness (ie, hemiparesis or paraparesis)
Elevated ICP/cerebral edema	N/A	N/A	Focal/local edema via neuroimaging	Diffuse cerebral edema via neuroimaging; decerebrate/decorticate posturing; papilledema, cranial nerve VI palsy, or Cushing triad


## ICE

- **Orientation:** Orientate to current mo, yr, city, hospital (4 points) 定向能力: 對年份、月份、城市、醫院的定向能力 (4 分)
- **Naming:** Name 3 objects, such as a clock, pen, or button (3 points) 命名能力: 能夠命名三個物體 (如時鐘、筆、鈕扣) (3 分)
- **Following commands:** Follow simple commands, such as “show me 2 fingers” (1 point) : 遵從指令能力: 能夠遵從簡單指令 (如“給我看兩根手指”或“閉上眼睛並伸出舌頭”) (1 分)
- **Writing:** Write a standard sentence, such as “Our national bird is a bald eagle” (1 point) 寫作能力: 能夠寫出一個標準句子 (如“我要趕快康復”) (1 分)
- **Attention:** Count backward by 10, starting at 100 (1 point) : 注意力: 能夠倒數, 從 100 開始每次減 10 (1 分)

# Toxicity Mitigation



# Bispecific Antibody management in B cell lymphoma



# Monitoring and Managing Cytopenias

Monitor CBC at baseline and periodically during treatment

Withhold agent if severe anemia, thrombocytopenia, and neutropenia per PI

Severe and long-lasting neutropenia poses increased infection risk

Administer appropriate infection prophylaxis

Administer growth factor support per institutional guidelines



# Infection Prophylaxis and Vaccinations

- Complete outstanding vaccinations  $\geq 2$  wk prior to therapy start (eg, influenza, pneumococcal, COVID-19)
  - Delay postinfusion vaccinations for 3-6 mo after bispecific antibody therapy
- Optimal prophylaxis duration has not been established, but recommended for up to 6 mo following treatment
- Monitor immunoglobulin levels

Antibacterial Prophylaxis	Antiviral Prophylaxis	Antifungal Prophylaxis
Recommend for patients at high risk of infection	HSV/VZV prophylaxis in all patients	<ul style="list-style-type: none"><li>▪ PJP prophylaxis recommended</li><li>▪ Other antifungal prophylaxis recommended for patients at high risk of fungal infection</li></ul>



# Managing Infections Associated With Bispecific Antibodies

- Withhold until resolution; consider permanent discontinuation for grade 4 infections
- Manage infections in accordance with institutional policies and susceptibility patterns
  - Consult with infectious disease specialist
- Utilize targeted therapy if the infectious organism can be identified
- Consider IVIG for recurrent infections in accordance with institutional policies

Bacterial Infections	Viral Infections	Fungal Infections
<ul style="list-style-type: none"><li>▪ Empiric antibacterial agents based on infection site</li><li>▪ Concomitant neutropenia: broad spectrum agents (third- or fourth-generation cephalosporin or carbapenem)</li><li>▪ Reserve vancomycin for specific indications</li></ul>	<ul style="list-style-type: none"><li>▪ Management based on type of virus and institutional protocol</li><li>▪ Examples include influenza, VZV, CMV, EBV, RSV, COVID-19</li></ul>	<ul style="list-style-type: none"><li>▪ Localized candidiasis: fluconazole</li><li>▪ Invasive candidiasis: echinocandin</li><li>▪ PJP: trimethoprim-sulfamethoxazole or atovaquone or primaquine with sulfonamide</li></ul>

# Multiple myeloma




Fig 1 | Multiple myeloma treatments—timeline of drug discovery and five year relative survival (using data from the Surveillance, Epidemiology, and Ends Results program).

Data for year of diagnosis and relative survival are: 1975, 26.5% (observed); 1980, 26.0% (observed); 1985, 27.4% (observed); 1990, 29.9% (observed); 1995, 33.5% (observed); 2000, 34.6% (observed); 2005, 47.1% (observed); 2010, 53.6% (observed); 2015, 55.3% (modelled)




Fig 2 | Recent immunotherapeutic approaches to treat multiple myeloma. CAR=chimeric antigen receptor; TCR=T cell receptor; MHC=major histocompatibility complex; BCMA=B cell maturation antigen; PD-L1=programmed death-ligand 1; PD-1=programmed cell death protein 1

Antibody Name	Trial Name (Study Patient Number)	Indication	Comparative Protocol	Comparative ORR	Comparative PFS	Comparative Overall Survival (OS)	Adverse Events	Source of Journal
<b>Blinatumomab</b> CD3 × CD19	TOWER (405 pts)	R/R B-Cell Precursor ALL	Standard Chemotherapy	44% (B) vs 25% (C)	7.7 VS 4.0 months	20.7 VS vs. 15.8 months (Chemotherapy)	CRS , Neurotoxicity	NEJM 2017;376:836-847
<b>Teclistamab</b> CD3 × BCMA	MajesTEC-1 (165 pts)	R/R Multiple Myeloma	Pomalidomide + Dexamethasone	63% (Teclistamab) vs. 39% (P + D)	11.3 months (Teclistamab) vs. 6.7 months (P +D)	Not yet mature in published data	CRS, Neutropenia, Thrombocytopenia	N Engl J Med 2022;387:2235-2246
<b>Amivantamab</b> EGFR × MET	CHRYSALIS (129 pts)	NSCLC with EGFR Exon 20 Insertion Mutations	Platinum-based Chemotherapy	40% (Amivantamab) vs. 20% (C)	8.3 (A) vs. 4.2 months (Chemotherapy)	22.8 months (Amivantamab) vs. 14.7 months (Chemotherapy)	Rash, Paronychia, Diarrhea, Interstitial lung disease	J Clin Oncol 2021;39:3391-3402

# Small cell lung cancer

Antibody Name	Trial Name (Study Patient N)	Indication	Comparative Protocol	Comparative ORR	Comparative PFS	Comparative Overall Survival (mOS)	Adverse Events	Source of Journal
Tarlatamab CD3 x DLL3	DeLLphi-300 (152 pts)	R/R Small Cell Lung Cancer (SCLC) with DLL3 expression		25%, 35.3 months (q2 weeks)	mDOR : 11.2 months CNS tumor shrinkage of $\geq 30\%$ was observed in 62.5% of patients with baseline CNS lesion of $\geq 10$ mm	1. 17.5 months (once d1, d8 a 21 cycles 20.3 months (10mgq 2 wks) )	Cytokine release syndrome, Anemia, Dyspnea	J Clin Oncol . 2024 Oct 10;42(29):3392-3399




# Mechanism of resistance

(A) tumor cell–intrinsic mechanisms,

(B) T-cell intrinsic mechanisms,

(C) T-cell extrinsic mechanisms,



Antigen loss and activation of immune-evasive gene expression programs,

Activation of regulatory T-cells, downregulation of the T-cell receptor, and development of T-cell exhaustion,

Recruitment of immunosuppressive myeloid and/or stromal cells. CAF, cancer-associated fibroblast; IL-10, interleukin-10; MDSC, myeloid-derived suppressor cell

PD-1, programmed death 1; PD-L1, programmed death ligand 1; TAM, tumor-associated macrophage; Teff, effector T cell; Texh, exhausted T cell; TGF-β, transforming growth factor beta; Tim-3, T-cell immunoglobulin mucin-3; Treg, regulatory T cell.

# Can we do better

- Targeting when tumor burden low (MRD )
- Bring treatment to earlier lines before resistance
- Combination therapy : Chemotherapy, immunomodulatory, targeted

# Optimal combinations

最佳的治療組合策略以達成 BCMA/CD3 $\epsilon$  雙特異性抗體 (BsAb) 在多發性骨髓瘤 (MM) 中持久的療效

**A. IMiD 藥物 Pomalidomide** 對骨髓瘤細胞 (細胞毒性作用) 及免疫細胞 (刺激作用) 產生多方面的影響。然而，矛盾的是，Pomalidomide 在 BsAb 治療過程中會促進 T 細胞的過度活化及衰竭，最終導致腫瘤復發。

**B. Cyclophosphamide** 是一種烷化劑，具有腫瘤減量的效果，同時也是一種淋巴耗竭劑。在與 BCMA/CD3 $\epsilon$  BsAb 聯合使用時，能夠適度調控 T 細胞的活化，減輕 T 細胞衰竭，改變腫瘤微環境，並獨特地誘導持久的抗多發性骨髓瘤免疫反應。

Treg：調節性 T 細胞。

